Cardiometabolic Disorders

Top Story

FDA approves evolocumab as LDL-lowering therapy in certain patients

August 27, 2015

The FDA has approved evolocumab, a PCSK9 inhibitor, for lowering LDL in adults with heterozygous or homozygous familial hypercholesterolemia or clinical atherosclerotic CVD, according to a press release from the agency.

Evolocumab (Repatha, Amgen) is intended for use in addition to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic CVD, and in addition to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH), according to an Amgen press release.

In the Journals

Extra virgin olive oil use may improve postprandial glucose, cholesterol

August 24, 2015
Adults consuming extra virgin olive oil as part of a Mediterranean-style meal had significantly lower glycemic markers and improved LDL cholesterol levels when compared…
Caroline Fox In the Journals

Updated guidelines address CVD prevention in adults with type 2 diabetes

August 19, 2015
The American Diabetes Association and the American Heart Association recently released a revised joint scientific statement outlining best practices to reduce…
In the Journals

CV risk factors, obesity common in women undergoing hysterectomy

August 18, 2015
In a recent study, women who underwent hysterectomy with ovarian conservation had a higher frequency of CV risk factors, particularly obesity.The Mayo Clinic Study of…
CME
Obesity Consults

Obesity Consults: Volume 2, Number 5
Practical Guide to Medications Approved for Chronic Weight Management

This activity is supported by educational grants from Eisai, Inc. and Vivus, Inc.

Several pharmacologic options for the management of obesity have been approved by the US FDA, giving clinicians a range…
More »
Meeting News Coverage Video
thumbnail for video 3861437055001

Lee M. Kaplan, MD, PhD: Individualized approach to obesity treatment most likely to succeed

October 27, 2014
BOSTON — In this video, Lee M. Kaplan, MD, PhD, director of the Obesity, Metabolism and Nutrition Institute at…
More »
CME
Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
FDA News

FDA approves evolocumab as LDL-lowering therapy in certain patients

August 27, 2015
The FDA has approved evolocumab, a PCSK9 inhibitor, for lowering LDL in adults with heterozygous or homozygous familial hypercholesterolemia or…
In the Journals

Extra virgin olive oil use may improve postprandial glucose, cholesterol

August 24, 2015
Adults consuming extra virgin olive oil as part of a Mediterranean-style meal had significantly lower glycemic markers and improved LDL cholesterol…
Caroline Fox In the Journals

Updated guidelines address CVD prevention in adults with type 2 diabetes

August 19, 2015
The American Diabetes Association and the American Heart Association recently released a revised joint scientific statement outlining best practices…
In the Journals

CV risk factors, obesity common in women undergoing hysterectomy

August 18, 2015
In a recent study, women who underwent hysterectomy with ovarian conservation had a higher frequency of CV risk factors, particularly obesity.The…
Vera Bittner In the Journals

Intensive medical therapy controls risk factors, improves outcomes in diabetes, CHD

August 11, 2015
Through protocol-guided intensive medical therapy, clinicians were able to achieve simultaneous control of multiple risk factors in patients with…
In the Journals

Screening men with erectile dysfunction may detect diabetes

July 30, 2015
Men with erectile dysfunction are more likely to have undiagnosed diabetes compared with those without erectile dysfunction, according to recent…
Jonathan Cedernaes In the Journals

One night of sleep loss may affect circadian genes, metabolic response

July 28, 2015
One night of sleep loss can alter “clock genes” in the body, potentially leading to metabolic effects, including insulin resistance…
James Floyd In the Journals

CV risk similar for second-line diabetes drugs plus metformin

July 27, 2015
Adults with type 2 diabetes using metformin combined with insulin have a similar cardiovascular risk when compared with adults using metformin…
FDA NewsPerspective

FDA approves alirocumab for lowering of LDL in certain patients

July 24, 2015
The FDA and Sanofi/Regeneron announced that the agency has approved alirocumab, a PCSK9 inhibitor, for lowering of LDL in addition to diet and…
Samar El Khoudary In the Journals

Heart fat volume related to menopausal status

July 20, 2015
Compared with premenopausal and early perimenopausal women regardless of age, obesity and other covariates, greater volumes of cardiovascular fat…
More Headlines »
morganatic-roan
morganatic-roan